BR112016004922A2 - - Google Patents
Info
- Publication number
- BR112016004922A2 BR112016004922A2 BR112016004922A BR112016004922A BR112016004922A2 BR 112016004922 A2 BR112016004922 A2 BR 112016004922A2 BR 112016004922 A BR112016004922 A BR 112016004922A BR 112016004922 A BR112016004922 A BR 112016004922A BR 112016004922 A2 BR112016004922 A2 BR 112016004922A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B1/00—Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Manufacturing & Machinery (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361878227P | 2013-09-16 | 2013-09-16 | |
| US61/878,227 | 2013-09-16 | ||
| US201461939332P | 2014-02-13 | 2014-02-13 | |
| US61/939,332 | 2014-02-13 | ||
| PCT/GB2014/052787 WO2015036792A1 (en) | 2013-09-16 | 2014-09-12 | Therapeutic polymeric nanoparticles and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112016004922A2 true BR112016004922A2 (https=) | 2017-08-01 |
| BR112016004922B1 BR112016004922B1 (pt) | 2022-08-23 |
Family
ID=51619214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016004922-5A BR112016004922B1 (pt) | 2013-09-16 | 2014-09-12 | Nanopartículas poliméricas terapêuticas e composição farmacêutica compreendendo as mesmas |
Country Status (38)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9428470B2 (en) | 2014-02-13 | 2016-08-30 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| SI3104838T1 (sl) * | 2014-02-13 | 2020-04-30 | Pfizer Inc. | Terapevtski nanodelci, ki vsebujejo terapevtsko sredstvo, in postopki za izdelovanje in uporabo omenjenih nanodelcev |
| WO2017081606A1 (en) * | 2015-11-10 | 2017-05-18 | Pfizer Inc. | Methods of determining features of polymeric nanoparticles that include a therapeutic agent |
| EP3380113A1 (en) * | 2015-11-25 | 2018-10-03 | Pfizer Inc. | Therapeutic nanoparticles comprising an antibiotic and methods of making and using same |
| JP6579948B2 (ja) * | 2015-12-24 | 2019-09-25 | 株式会社日立ハイテクノロジーズ | 生体ポリマを分析するための測定試薬及び分析デバイス |
| EP3432864B1 (en) * | 2016-03-22 | 2020-05-06 | Pfizer Inc | Process for preparing therapeutic nanoparticles |
| US11517620B2 (en) | 2017-03-29 | 2022-12-06 | Terumo Kabushiki Kaisha | Adjuvant composition, and vaccine composition and drug kit each containing the same |
| TW202019440A (zh) | 2018-07-30 | 2020-06-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| TW202023568A (zh) | 2018-07-30 | 2020-07-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
| EP3860577A4 (en) * | 2019-02-02 | 2022-08-10 | Nanobrid Innovations Private Limited | LIPID-POLYMER HYBRID NANOPARTICLE |
| US11123734B2 (en) | 2019-07-31 | 2021-09-21 | CytoVale Inc. | System and method for immune activity determination |
| WO2021037933A1 (en) | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| WO2021224381A1 (en) | 2020-05-07 | 2021-11-11 | Astrazeneca Ab | Combination therapy for treating cancer |
| WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
| WO2022192139A1 (en) | 2021-03-10 | 2022-09-15 | Astrazeneca Ab | Aurora kinase b inhibitors for use for treating cancer |
| US11548003B1 (en) * | 2022-01-13 | 2023-01-10 | CytoVale Inc. | System and method for determining an immune activation state |
| US11592371B1 (en) | 2022-01-13 | 2023-02-28 | CytoVale Inc. | System and method for determining an immune activation state |
| US11964281B2 (en) | 2022-02-03 | 2024-04-23 | CytoVale Inc. | System and method for correcting patient index |
| WO2023150246A1 (en) * | 2022-02-04 | 2023-08-10 | Virginia Commonwealth University | Sustained release formulations and methods of use thereof |
Family Cites Families (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL89029A (en) | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them |
| GB9017479D0 (en) | 1990-08-09 | 1990-09-26 | Ici Plc | Process |
| GB9102727D0 (en) | 1991-02-08 | 1991-03-27 | Ici Plc | Pharmaceutical agent |
| US5721237A (en) | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5409930A (en) | 1991-05-10 | 1995-04-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| GB9510757D0 (en) | 1994-09-19 | 1995-07-19 | Wellcome Found | Therapeuticaly active compounds |
| TW321649B (https=) | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
| EP0805678B1 (en) | 1995-01-05 | 2003-10-29 | THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN | Surface-modified nanoparticles and method of making and using same |
| ES2177592T3 (es) | 1995-07-05 | 2002-12-16 | Europ Economic Community | Nanoparticulas biocompatibles y biodegradables para la absorcion y administracion de medicamentos proteinicos. |
| GB9514265D0 (en) | 1995-07-13 | 1995-09-13 | Wellcome Found | Hetrocyclic compounds |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| KR100860295B1 (ko) | 1998-10-08 | 2008-09-25 | 아스트라제네카 아베 | 퀴나졸린 유도체 |
| FI982733L (fi) | 1998-12-17 | 2000-06-18 | Orion Yhtymae Oyj | Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia |
| GB9922171D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Chemical compounds |
| US7709479B1 (en) | 1999-09-21 | 2010-05-04 | Astrazeneca | Quinazoline derivatives and their use as pharmaceuticals |
| US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
| ATE394102T1 (de) | 2000-06-28 | 2008-05-15 | Astrazeneca Ab | Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren |
| US6610677B2 (en) | 2000-09-15 | 2003-08-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| EP1372385A1 (en) | 2001-03-30 | 2004-01-02 | Rhodia Inc. | Aqeuous suspension of nanoparticles comprising an agrochemical active ingredient |
| WO2003000188A2 (en) | 2001-06-21 | 2003-01-03 | Ariad Pharmaceuticals, Inc. | Novel quinazolines and uses thereof |
| GB0124299D0 (en) | 2001-10-10 | 2001-11-28 | Astrazeneca Ab | Crystal structure of enzyme and uses thereof |
| AU2002334939A1 (en) | 2001-10-12 | 2003-04-22 | Eugene R. Cooper | Compositions having a combination of particles for immediate release and for controlled release |
| DE60234125D1 (de) | 2001-12-24 | 2009-12-03 | Astrazeneca Ab | E inhibitoren |
| KR20050037992A (ko) | 2002-06-05 | 2005-04-25 | 유니버시티 오브 플로리다 | 안약 전달 장치 |
| WO2004006959A1 (en) | 2002-07-16 | 2004-01-22 | Elan Pharma International, Ltd | Liquid dosage compositions of stable nanoparticulate active agents |
| DE60325742D1 (de) | 2002-07-31 | 2009-02-26 | Alza Corp | Injizierbare multimodale polymere depotzusammensetzungen und ihre verwendungen |
| ES2290529T3 (es) * | 2002-12-24 | 2008-02-16 | Astrazeneca Ab | Derivados de fosfonooxiquinazolina y su uso farmaceutico. |
| EP1608359A4 (en) | 2003-04-03 | 2011-08-17 | Jessie L-S Au | DRUG-LOADING PARTICLES TARGETING TUMORS |
| US7727969B2 (en) | 2003-06-06 | 2010-06-01 | Massachusetts Institute Of Technology | Controlled release nanoparticle having bound oligonucleotide for targeted delivery |
| WO2005009357A2 (en) * | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| US9028829B2 (en) | 2004-02-20 | 2015-05-12 | The Children's Hospital Of Philadelphia | Uniform field magnetization and targeting of therapeutic formulations |
| ES2246694B1 (es) | 2004-04-29 | 2007-05-01 | Instituto Cientifico Y Tecnologico De Navarra, S.A. | Nanoparticulas pegiladas. |
| US8945629B2 (en) | 2004-09-10 | 2015-02-03 | University Of Wyoming | Nanoparticles for cytoplasmic drug delivery to cancer cells |
| EP1871345B1 (en) | 2005-04-12 | 2012-08-01 | Elan Pharma International Limited | Nanoparticulate erlotinib formulations |
| US20090022806A1 (en) | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
| WO2007069272A2 (en) | 2005-10-21 | 2007-06-21 | Panacea Biotec Limited | Pharmaceutical composition comprising at least one anticancer drug and at least one polymer |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| WO2010009146A1 (en) | 2008-07-15 | 2010-01-21 | University Of Kansas | Nanoclusters for delivery of poorly water soluble drug nanoparticles |
| US8916206B2 (en) | 2005-12-26 | 2014-12-23 | Ltt Bio-Pharma Co., Ltd. | Nanoparticles containing water-soluble non-peptide low-molecular weight drug |
| ES2776100T3 (es) | 2006-03-31 | 2020-07-29 | Massachusetts Inst Technology | Sistema para el suministro dirigido de agentes terapéuticos |
| US8367113B2 (en) | 2006-05-15 | 2013-02-05 | Massachusetts Institute Of Technology | Polymers for functional particles |
| GB0609621D0 (en) * | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Novel co-crystal |
| GB0609617D0 (en) | 2006-05-16 | 2006-06-21 | Astrazeneca Ab | Process & intermediate |
| US20110052697A1 (en) | 2006-05-17 | 2011-03-03 | Gwangju Institute Of Science & Technology | Aptamer-Directed Drug Delivery |
| WO2007150030A2 (en) | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| BRPI0714782A2 (pt) | 2006-07-31 | 2013-07-16 | Senju Pharma Co | preparaÇço lÍquida aquosa contendo composto de amida |
| US20100144845A1 (en) | 2006-08-04 | 2010-06-10 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
| WO2008147456A2 (en) | 2006-11-20 | 2008-12-04 | Massachusetts Institute Of Technology | Drug delivery systems using fc fragments |
| WO2008091465A2 (en) | 2006-12-21 | 2008-07-31 | Wayne State University | Peg and targeting ligands on nanoparticle surface |
| WO2008109163A1 (en) | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc. | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| WO2008124632A1 (en) | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
| BRPI0810899A2 (pt) | 2007-04-13 | 2014-10-29 | Univ North Texas | Formulação de nanopartículas de plga ativadas carregadas com agente ativo para substâncias nano-terapêuticas anticâncer direcionais. |
| CN101678113B (zh) | 2007-05-14 | 2012-05-30 | 日本株式会社Ltt生物医药 | 缓释性的含有带负电荷基团的低分子药物的纳米粒子 |
| SI2200588T1 (sl) | 2007-09-25 | 2019-08-30 | Solubest Ltd. | Sestavki, ki obsegajo lipofilne aktivne spojine, in postopek za njihovo pripravo |
| US8974814B2 (en) | 2007-11-12 | 2015-03-10 | California Institute Of Technology | Layered drug delivery polymer monofilament fibers |
| WO2009070302A1 (en) | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
| EP2229147A2 (en) | 2007-12-03 | 2010-09-22 | The Johns Hopkins University | Methods of synthesis and use of chemospheres |
| KR100961880B1 (ko) | 2007-12-12 | 2010-06-09 | 중앙대학교 산학협력단 | 밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제 |
| US20110182946A1 (en) | 2008-03-17 | 2011-07-28 | Board Of Regents, The University Of Texas System | Formation of Nanostructured Particles of Poorly Water Soluble Drugs and Recovery by Mechanical Techniques |
| MX2010011165A (es) * | 2008-04-10 | 2011-02-22 | Abraxis Bioscience Llc | Composiciones de derivados de taxano hidrofobos y sus usos. |
| US20090312402A1 (en) | 2008-05-20 | 2009-12-17 | Contag Christopher H | Encapsulated nanoparticles for drug delivery |
| CN102099016A (zh) * | 2008-06-16 | 2011-06-15 | 佰恩德生物科学股份有限公司 | 载药的聚合物纳米微粒及其制备和使用方法 |
| JP2012501965A (ja) | 2008-06-16 | 2012-01-26 | バインド バイオサイエンシズ インコーポレイテッド | 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法 |
| ES2721850T3 (es) | 2008-06-16 | 2019-08-05 | Pfizer | Nanopartículas poliméricas terapéuticas que comprenden alcaloides vinca y procedimientos de fabricación y uso de las mismas |
| WO2010005740A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences, Inc. | Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles |
| US8613951B2 (en) | 2008-06-16 | 2013-12-24 | Bind Therapeutics, Inc. | Therapeutic polymeric nanoparticles with mTor inhibitors and methods of making and using same |
| US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
| WO2010042555A2 (en) | 2008-10-06 | 2010-04-15 | The Brigham And Women's Hospital, Inc. | Particles with multiple functionalized surface domains |
| US20110125090A1 (en) | 2008-11-13 | 2011-05-26 | Peyman Gholam A | Ophthalmic drug delivery system and method |
| WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| US20100216804A1 (en) | 2008-12-15 | 2010-08-26 | Zale Stephen E | Long Circulating Nanoparticles for Sustained Release of Therapeutic Agents |
| CN102365372B (zh) * | 2009-01-31 | 2016-05-25 | Abbvie公司 | 预测和监控对于Aurora激酶B抑制剂疗法的应答的标记 |
| US20120052041A1 (en) | 2009-02-04 | 2012-03-01 | The Brigham And Women's Hospital, Inc. | Polymeric nanoparticles with enhanced drug-loading and methods of use thereof |
| CA2768968A1 (en) * | 2009-09-29 | 2011-04-07 | Eyegate Pharmaceuticals, Inc. | Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| ES2780156T3 (es) | 2009-12-15 | 2020-08-24 | Pfizer | Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular |
| JP6175237B2 (ja) | 2009-12-15 | 2017-08-02 | ファイザー・インク | コルチコステロイドを含む治療用ポリマーナノ粒およびそれを製造かつ使用する方法 |
| JP5898627B2 (ja) | 2009-12-15 | 2016-04-06 | バインド セラピューティックス インコーポレイテッド | エポチロンを含む治療用ポリマーナノ粒子ならびにそれを製造および使用する方法 |
| ES2384060B1 (es) | 2010-03-24 | 2013-09-23 | Lipotec S.A. | Cápsulas de nanopartículas lipídicas. |
| US8207290B2 (en) | 2010-03-26 | 2012-06-26 | Cerulean Pharma Inc. | Methods and systems for generating nanoparticles |
| AU2011258165B2 (en) | 2010-05-26 | 2016-11-17 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
| CN103221070B (zh) | 2010-08-30 | 2019-07-12 | 哈佛大学校长及研究员协会 | 用于狭窄病变和溶解血栓疗法的切变控制释放 |
| US10307372B2 (en) | 2010-09-10 | 2019-06-04 | The Johns Hopkins University | Rapid diffusion of large polymeric nanoparticles in the mammalian brain |
| ES2386177B1 (es) | 2010-09-21 | 2013-09-23 | Lipotec, S.A. | Nanocapsulas conteniendo microemulsiones |
| WO2012040513A1 (en) | 2010-09-22 | 2012-03-29 | The Board Of Regents Of The University Of Texas System | Compositions and methods for the delivery of beta lapachone |
| EP2627317A4 (en) | 2010-10-15 | 2014-08-20 | Glaxo Group Ltd | MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE |
| EP2629760A4 (en) | 2010-10-22 | 2014-04-02 | Bind Therapeutics Inc | THERAPEUTIC NANOPARTICLES CONTAINING COPOLYMERS OF HIGH MOLECULAR WEIGHT |
| KR101304597B1 (ko) | 2010-11-02 | 2013-09-12 | 한남대학교 산학협력단 | 멀티-코어 구조를 갖는 생체적합성 입자의 제조방법 및 이에 의해 제조된 멀티-코어 구조를 갖는 생체적합성 입자 |
| FR2967581B1 (fr) | 2010-11-19 | 2012-12-28 | Sanofi Aventis | Conjugues polymeriques de principes actifs, leur procede de preparation et leurs intermediaires polymeriques |
| CN105853393A (zh) | 2011-01-24 | 2016-08-17 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 用于药物的经皮递送和全身性递送的纳米粒子 |
| US20140035438A1 (en) | 2011-04-12 | 2014-02-06 | Massachusetts Institute Of Technology | Passive, Self-Tuning Energy Harvester for Extracting Energy From Rotational Motion |
| EP2747761A1 (en) | 2011-09-22 | 2014-07-02 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
| WO2013090840A1 (en) | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors |
| ES2685743T3 (es) | 2012-02-29 | 2018-10-11 | Merck Patent Gmbh | Procedimiento para la fabricación de nanopartículas cargadas con principio activo |
| JP6138904B2 (ja) | 2012-03-16 | 2017-05-31 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート |
| MX356097B (es) | 2012-09-17 | 2018-05-14 | Pfizer Inc Star | Proceso para la preparacion de nanoparticulas terapeuticas. |
| BR112015005878A2 (pt) * | 2012-09-17 | 2017-07-04 | Bind Therapeutics Inc | nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas |
| AU2014233757B2 (en) * | 2013-03-18 | 2017-12-21 | Genoscience Pharma | Quinolines derivatives as novel anticancer agents |
-
2014
- 2014-09-12 ES ES14772420.7T patent/ES2640648T3/es active Active
- 2014-09-12 CN CN201480050773.9A patent/CN105555315B/zh active Active
- 2014-09-12 PT PT171815657T patent/PT3311845T/pt unknown
- 2014-09-12 AP AP2016009088A patent/AP2016009088A0/xx unknown
- 2014-09-12 LT LTEP14772420.7T patent/LT3046584T/lt unknown
- 2014-09-12 PL PL17181565T patent/PL3311845T3/pl unknown
- 2014-09-12 RS RS20170945A patent/RS56362B1/sr unknown
- 2014-09-12 HU HUE14772420A patent/HUE034490T2/en unknown
- 2014-09-12 HR HRP20171365TT patent/HRP20171365T1/hr unknown
- 2014-09-12 RU RU2016110351A patent/RU2682332C2/ru active
- 2014-09-12 DK DK14772420.7T patent/DK3046584T3/en active
- 2014-09-12 WO PCT/GB2014/052787 patent/WO2015036792A1/en not_active Ceased
- 2014-09-12 ES ES17181565T patent/ES2784423T3/es active Active
- 2014-09-12 EP EP14772420.7A patent/EP3046584B1/en active Active
- 2014-09-12 DK DK17181565.7T patent/DK3311845T3/da active
- 2014-09-12 JP JP2016542377A patent/JP6543258B2/ja active Active
- 2014-09-12 EP EP17181565.7A patent/EP3311845B1/en active Active
- 2014-09-12 PT PT147724207T patent/PT3046584T/pt unknown
- 2014-09-12 HU HUE17181565A patent/HUE048498T2/hu unknown
- 2014-09-12 SM SM20170442T patent/SMT201700442T1/it unknown
- 2014-09-12 MY MYPI2016700906A patent/MY191804A/en unknown
- 2014-09-12 CA CA2922279A patent/CA2922279C/en active Active
- 2014-09-12 SI SI201430374T patent/SI3046584T1/sl unknown
- 2014-09-12 RS RS20200361A patent/RS60093B1/sr unknown
- 2014-09-12 PL PL14772420T patent/PL3046584T3/pl unknown
- 2014-09-12 AU AU2014320088A patent/AU2014320088B2/en active Active
- 2014-09-12 KR KR1020167009468A patent/KR102307175B1/ko active Active
- 2014-09-12 SI SI201431532T patent/SI3311845T1/sl unknown
- 2014-09-12 BR BR112016004922-5A patent/BR112016004922B1/pt active IP Right Grant
- 2014-09-12 ME MEP-2017-231A patent/ME02860B/me unknown
- 2014-09-12 PE PE2016000354A patent/PE20160930A1/es unknown
- 2014-09-12 TN TN2016000077A patent/TN2016000077A1/en unknown
- 2014-09-12 SG SG11201601218PA patent/SG11201601218PA/en unknown
- 2014-09-12 MX MX2016003437A patent/MX370490B/es active IP Right Grant
- 2014-09-12 SM SM20200162T patent/SMT202000162T1/it unknown
- 2014-09-12 LT LTEP17181565.7T patent/LT3311845T/lt unknown
- 2014-09-15 TW TW103131811A patent/TWI644674B/zh active
- 2014-09-15 UY UY35738A patent/UY35738A/es not_active Application Discontinuation
- 2014-09-15 US US14/485,875 patent/US10047072B2/en active Active
-
2016
- 2016-02-18 IL IL244174A patent/IL244174B/en active IP Right Grant
- 2016-03-10 DO DO2016000061A patent/DOP2016000061A/es unknown
- 2016-03-10 GT GT201600050A patent/GT201600050A/es unknown
- 2016-03-10 CL CL2016000556A patent/CL2016000556A1/es unknown
- 2016-03-11 NI NI201600037A patent/NI201600037A/es unknown
- 2016-03-14 CR CR20160130A patent/CR20160130A/es unknown
- 2016-03-14 PH PH12016500499A patent/PH12016500499B1/en unknown
- 2016-04-04 ZA ZA2016/02201A patent/ZA201602201B/en unknown
-
2017
- 2017-07-27 AU AU2017208307A patent/AU2017208307B2/en active Active
- 2017-09-13 CY CY20171100964T patent/CY1119398T1/el unknown
- 2017-09-27 ZA ZA2017/06497A patent/ZA201706497B/en unknown
-
2018
- 2018-06-27 US US16/019,982 patent/US10577351B2/en active Active
-
2020
- 2020-03-12 HR HRP20200407TT patent/HRP20200407T1/hr unknown
- 2020-12-24 IL IL279767A patent/IL279767B/en unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/09/2014, OBSERVADAS AS CONDICOES LEGAIS |